HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Syme, R. Articles by Glück, S. Search for Related Content PubMed PubMed Citation Articles by Syme, R. Articles by Glück, S.

Comparison of CD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients

^a Department of Oncology, Tom Baker Cancer Centre, Calgary, Canada;
^b Cancer Biology Research Group, Faculty of Medicine, University of Calgary, Calgary, Canada;
^c Department of Medicine, Tom Baker Cancer Centre, Calgary, Canada; and
^d University of Miami School of Medicine, Miami, Florida, USA

Key Words. Dendritic cells • CD34⁺ cells • Peripheral blood mononuclear cells • Immunotherapy • Monocyte

Correspondence: Rachel Syme, Ph.D., Operations Manager, Clinical Research Program, Department of Oncology, Tom Baker Cancer Centre, 1331 29th Street NW, Calgary, AB, T2N 4N2, Canada. Telephone: 403-944-8388; Fax: 403-283-1158; e-mail: rachelsy{at}cancerboard.ab.ca

Dendritic cells (DCs) are potent antigen-presenting cells that are integral to the initiation of T-cell immunity. Two cell types can be used as a source for generating DCs: monocytes and CD34⁺ stem cells. Despite many investigations characterizing DCs, none have performed a direct paired comparison of monocyte and stem cell–derived DCs. Therefore, it is unclear whether one cell source has particular advantages over the other, or whether inherent differences exist between the two populations. We undertook the following study to determine if there were any differences in DCs generated from monocytes or CD34⁺ cells from mobilized peripheral blood. DCs were generated by culturing the adherent cells (monocytes) in interleukin-4 and GM-CSF for 7 days, or by culturing nonadherent cells (CD34⁺) in the presence of GM-CSF and tumor necrosis factor alpha for 14 days. The resulting DCs were compared morphologically, phenotypically, functionally, and by yield. We could generate morphologically and phenotypically similar DCs. Differences were encountered when expression levels of some cell surface markers were examined (CD86, HLA-DR). There was no difference in how the DCs performed in a mixed lymphocyte reaction (p = .3). Further, no statistical difference was discovered when we examined cellular (DC) yield (p = .1); however, there was a significant difference when yield was normalized to the starting number of monocytes or CD34⁺ cells (p = .016). Together, these data demonstrate that differences do exist between monocyte-derived DCs and CD34-derived DCs from the same cellular product (apheresis) from the same individual.